This is the authors' abstract. We don't add key points for this paper.
Introduction Bladder cancer remains a therapeutic challenge due to its high recurrence and metastasis rates. Cancer-associated fibroblasts (CAFs) are recognized as pivotal regulators of the tumor microenvironment (TME), however the specific contribution of CTHRC1 + CAFs subsets to bladder cancer progression remains poorly defined. Methods CTHRC1 + CAFs were successfully isolated from human patient specimens and mouse xenograft models. To systematically evaluate the function of CTHRC1 + CAFs in bladder cancer, a comprehensive suite of assays was employed, including CCK-8, Transwell, murine xenograft models, ELISA, flow cytometry, and Western blotting. Results We found that CTHRC1 was predominantly expressed in CAFs, and CTHRC1 + CAFs promoted cell growth, migration and invasion of bladder cancer cells both in vitro and in vivo . Moreover, CTHRC1 + CAFs fostered an immunosuppressive tumor microenvironment by driving M2 macrophage polarization and Th2 differentiation, which subsequently suppressed the antitumor activity of CD8 + T cells. Mechanistically, CTHRC1 activated the PI3K/Akt/NF-κB pathway in CAFs and induced the secretion of various immunomodulatory cytokines, which regulated M2 macrophage polarization and Th2 differentiation. Conclusions These findings identify CTHRC1 + CAFs as key promoters of bladder cancer progression and immune evasion, suggesting CTHRC1 as a potential prognostic biomarker for bladder cancer.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: